While the GSH, Grx, and Trx systems operate via distinct enzymatic pathways they converge functionally to create a cooperative redox buffering machine
For example, Zepbound has a self-pay option without insurance: $349 per month for the starting 2.5 mg dose
The structural basis for this triple activity was elucidated through 2024 cryo-EM studies, which showed that retatrutides 26-amino acid backbone adopts distinct helical conformations at each receptor interface, explaining how balanced agonism across all three receptors is achievable without sacrificing binding affinity at any single target [9]
In order for GLP-1s to gain FDA approval for this use, they must go through two well-designed (large, randomized, double-blind, placebo-controlled) phase 3 clinical trials that, ideally, run for 6 to 12 months